Parkinson hastalarında tamsulosin tedavisinin alt üriner sistem belirtileri üzerine etkisi
Yükleniyor...
Dosyalar
Tarih
2008
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Bu çalışmada Benin Prostat Hiperplazisi (BPH) olan Parkinson Hastalarındaki (PH) alt üriner sistem belirtilerinin (AÜSB) şiddetini değerlendirmeyi ve bu olgularda tamsulosin tedavisinin objektif ve subjektif ölçütler üzerine olan etkisini araştırmayı amaçladık. Bu çalışmaya BPH ile birlikte PH olan 40 ve sadece BPH’sı olan 40 olmak üzere toplam 80 olgu alındı. Tüm olgular tedavi öncesi uluslar arası prostat semptom skoru (IPSS), yaşam kalitesi skoru (YK), maksimal idrar akım hızı (Qmax) ve ultrasonografi ile postvoid rezidü (PVR) tayini ile değerlendirildi. PH olan olgular ayrıca Birleşik Parkinson Hastalığı Değerlendirme Ölçeği (BPHDÖ) ile değerlendirildi. Olgulara tamsulosin 0.4 mg/gün tedavi başladı. Tedavi başladıktan 3 ay sonra hastalar objektif ve subjektif parametrelerle tekrar değerlendirilerek tamsulosin tedavisinin etkinliği değerlendirildi. PH grubundan üç olgu (%7.5) şiddetli hipotansif ataklardan dolayı çalışma dışı bırakıldı. Her iki gruptaki olguların demografik verileri arasında fark saptanmazken PH olgularının tedavi öncesi IPSS, YK ve Qmax değerleri kontrol grubuna göre daha düşük ve PVR değerleri ise daha yüksek bulundu (p<0.05). Her iki gruptaki olgular tamsulosin tedavisine iyi yanıt verirken, bu yanıt PH grubunda daha düşük oranda bulundu. PH süresi, BPHDÖ skorları ile subjektif ve objektif parametreler arasındaki ilişki incelendiğinde ise, PVR dışındaki tüm parametrelerin korele olduğu gözlendi. AÜSB olan PH’da tamsulosin tedavisi üriner belirtileri gidermede etkilidir. Fakat bu etki PH süresi ve şiddeti ile ters orantılı olarak azalmaktadır. Buna karşın AÜSB olan PH olgularında tamsulosin tedavisi belirtileri gidermede tedavi boyunca olguların yakın takip edilmesi koşuluyla verilebilir.
The aim of this study is to evaluate the intensity of lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH) with and without Parkinson&#8217;s disease (PD). We also investigated the efficacy of tamsulosin therapy in the management of the subjective and objective symptoms in these patients. Materials and Methods: This study included 80 (40 patients with and 40 without PD) clinically diagnosed BPH patients treated with tamsulosin. International Prostate Symptom score (IPSS), quality of life (QoL), maximum flow rate (Qmax) and post-void residual urine volume (PVR) were determined at baseline and after the 3 months of therapy. The PD group also evaluated with Unified Parkinson&#8217;s Disease Rating Scale (UPDRS). All patients had received tamsulosin 0.4 mg/per day for 3 months period. The relationship between PD duration and UPDRS and mean changes of IPSS, QoL, Qmax and PVR after tamsulosin therapy were also investigated in PD group. Results: Three patients (7.5%) in PD group were discontinuied the therapy due to the severe hypotension attack. Initial data of IPSS, QoL, Qmax and PVR were different between two groups (p<0.001). After tamsulosin treatment, LUTS improved significantly in both groups (p<0.05). Improvement rates of the IPSS, QoL, Qmax and PVR were significantly higher in non-PD group (p<0.05). When relationship were investigated between PD duration and UPDRS and mean changes of IPSS, QoL, Qmax and PVR after tamsulosin therapy, all parameters were found in correlation except PVR. Conclusion: Tamsulosin therapy appears to useful in PD patient with BPH. But its efficacy is changed with PD duration and severity. After all, tamsulosin therapy can be given to these patients group with close follow-up.
The aim of this study is to evaluate the intensity of lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH) with and without Parkinson&#8217;s disease (PD). We also investigated the efficacy of tamsulosin therapy in the management of the subjective and objective symptoms in these patients. Materials and Methods: This study included 80 (40 patients with and 40 without PD) clinically diagnosed BPH patients treated with tamsulosin. International Prostate Symptom score (IPSS), quality of life (QoL), maximum flow rate (Qmax) and post-void residual urine volume (PVR) were determined at baseline and after the 3 months of therapy. The PD group also evaluated with Unified Parkinson&#8217;s Disease Rating Scale (UPDRS). All patients had received tamsulosin 0.4 mg/per day for 3 months period. The relationship between PD duration and UPDRS and mean changes of IPSS, QoL, Qmax and PVR after tamsulosin therapy were also investigated in PD group. Results: Three patients (7.5%) in PD group were discontinuied the therapy due to the severe hypotension attack. Initial data of IPSS, QoL, Qmax and PVR were different between two groups (p<0.001). After tamsulosin treatment, LUTS improved significantly in both groups (p<0.05). Improvement rates of the IPSS, QoL, Qmax and PVR were significantly higher in non-PD group (p<0.05). When relationship were investigated between PD duration and UPDRS and mean changes of IPSS, QoL, Qmax and PVR after tamsulosin therapy, all parameters were found in correlation except PVR. Conclusion: Tamsulosin therapy appears to useful in PD patient with BPH. But its efficacy is changed with PD duration and severity. After all, tamsulosin therapy can be given to these patients group with close follow-up.
Açıklama
Anahtar Kelimeler
Üroloji ve Nefroloji
Kaynak
Türk Üroloji Dergisi/Turkish Journal of Urology
WoS Q Değeri
Scopus Q Değeri
Cilt
34
Sayı
1
